Omicron hammers disease-modifying drug options

Australia is fortunate to have stocks of one of the few agents maintaining efficacy, leading clinician says

The Omicron variant is undermining multiple COVID-19 treatments, although the monoclonal antibody most used in Australia is holding up well, a top immunologist says.

Professor Tony Kelleher.

A French preprint study published on bioRxiv last month found the Omicron variant was “totally or partially resistant” to nine different monoclonal antibodies being used or evaluated around the world.

But

Latest